Clinical trial
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
NCT00002337 · Otsuka America Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00002337 |
|---|---|
| Title | A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease |
| Official title | A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease |
| Lead sponsor | Otsuka America Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Vesnarinone |
| Enrollment | 56 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: